OTLK — Outlook Therapeutics, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1649989 ·
Last close
$1.65
Market Cap
$199.42M
52W High
$1.70
52W Low
$0.16
ADV30
31,798,718
Next earnings
2026-08-13
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 127,439 -21,888 -14,026,987 -4,453,081 21,892,406 7,748,226 50,887,177
Dec 2025 -1,207,833 -1,237,459 -13,483,952 -23,058,135 18,238,574 8,677,424 56,788,039
Sep 2025 -91,787 -1,008,302 -17,314,606 -13,292,769 18,584,183 8,083,085 50,771,844
Jun 2025 1,505,322 1,065,507 -15,748,680 -20,152,502 22,391,540 8,900,814 59,581,265

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-47,045,522
Investing CF
Financing CF
$47,237,435
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.48
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-633,220,979
Inventory
$3,344,242
Receivables
$2,719,828
ST Investments
EBIT TTM
$-62,197,332
Pretax Income TTM
$-62,511,116
Interest Exp TTM
$313,507
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$333,141
EBITDA
$-60,454,584
Free Cash Flow
$-25,471,416
Enterprise Value
$209,195,040
Total Cash
$7,748,226
Total Debt
$27,187,960
Shares Out
120,863,252
Trailing EPS
$-1.13
Book Value
$-0.28
ROE
ROA
-184.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 1,413,535 -67,061,666 -62,424,863 18,584,183 50,771,844 -51,829,437
Sep 2024 0 -71,703,235 -75,366,714 28,823,154 101,899,664 -68,793,858
Sep 2023 0 -53,126,382 -58,982,668 32,300,601 46,738,378 -42,973,398
Sep 2022 0 -63,070,753 -66,052,264 28,527,751 19,791,180 -56,674,559

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.22

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.50 · spot: $1.65 · call volume: 1,937 · put volume: 842
Expected Move to 2026-07-17: ±$0.70 (42.42%) — implied range $0.95$2.35 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LENZ LENZ Therapeutics, Inc. $198.79M $6.34
CGEN COMPUGEN LTD $188.22M $1.99
CHRS Coherus Oncology, Inc. $214.41M $1.39
VYGR Voyager Therapeutics, Inc. $218.73M $3.62
IKT Inhibikase Therapeutics, Inc. $221.81M $1.68

News headlines (Yahoo Finance, 1h cache)

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
2026-06-17 14:20 · Yahoo
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In
2026-06-16 20:08 · Yahoo
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision
2026-06-16 17:47 · Yahoo
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
2026-06-16 12:02 · Yahoo
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission
2026-06-14 13:08 · Yahoo
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal
2026-06-01 17:05 · Yahoo
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
2026-06-01 12:46 · Yahoo
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-05-28 20:00 · Yahoo
OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record
2026-05-28 17:38 · Yahoo
Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday
2026-05-27 05:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.